NVIDIA GTC 2026: Must-See Biotech and Pharma AI Breakthroughs Beyond Silicon Photonics and Memory

NVIDIA’s GTC 2026 conference runs from March 16 to 19 in San Jose. It spotlights AI’s transformation across industries. Biotech and healthcare shine as key focuses alongside memory and CPO topics. GeneOnline has curated key forums and insights from the conference, offering guidance ahead of the event so you can grasp the most important industry developments and the conference’s key highlights in a single article.

AI Adoption Blooms in Biotech and Pharma: 70% Now Use It Actively

NVIDIA Healthcare surveyed over 600 professionals in digital health, pharma, biotech, medtech, and payers. Results show strong growth. Seventy percent of organizations actively adopt AI, up from 63% in 2024. Sixty-nine percent use generative AI and large language models, rising from 54%.

Digital health leads with 78% adoption. Medtech follows at 74%. Generative AI helps with clinical documentation, patient communication, and coding. Predictive analytics improve demand forecasting and resource allocation. Agentic AI gains traction—47% of organizations use or evaluate it for multi-step workflows.

Medtech sees big wins in medical imaging (57%). Pharma and biotech highlight drug discovery as a top revenue driver (46%). Digital health providers value virtual assistants and chatbots (37%). Payers focus on administrative efficiency (39%).

Experts stress practical integration. Annabelle Painter from Visiba UK urged solving real clinical problems. Embed AI into existing workflows. John Nosta from NostaLab favored open-source models for customization and cost control. Strict governance matters for high-risk clinical use. Hippocratic AI demonstrated agentic AI for large-scale patient monitoring in real care flows.

Eli Lilly Launched LillyPod: The World’s First Pharma-Owned AI Factory

On February 26, 2026, Eli Lilly revealed LillyPod. This marks the first fully owned and operated AI factory in pharma. It uses 1,016 NVIDIA Blackwell Ultra GPUs in a DGX SuperPOD. The system delivers over 9,000 petaflops of extreme AI performance. Lilly built and launched it in just four months in Indianapolis.

Diogo Rau, Lilly’s EVP and Chief Information Officer, called it a milestone after 150 years of heritage. LillyPod advances the mission to improve global health. Yue Wang Webster, VP of Research Informatics, noted traditional wet labs test about 2,000 molecules yearly. LillyPod’s dry lab simulates billions of molecular hypotheses simultaneously. It breaks physical limits and accelerates discovery.

Four Must-Attend GTC 2026 Sessions on Biotech and Medical AI

Session 1: Open Models, Agentic AI, and Physical AI Create Healthcare’s Innovation Flywheel

Kimberly Powell, NVIDIA VP of Healthcare and Life Sciences, presents on March 16 at 3:00–3:40 p.m. PDT. In GTC 2026 She will show how open foundation models, agentic AI, and physical AI spark new applications. These span care delivery, drug discovery, and lab operations. They form a powerful flywheel effect. Tools include BioNeMo, Clara Guardian, Clara Holoscan, Parabricks, MONAI, NVIDIA NIM, and CUDA-Q.

Session 2: Building a Medical-Grade Real-Time AI Platform in Practice

Pietro Salvagnini and Nhan Ngo Dinh from Cosmo MedTech lead on March 19 at 2:00–2:50 a.m. PDT. They will demonstrate turning NVIDIA IGX and Holoscan into a reusable platform. Topics will cover system architecture, safety design, Holoscan graphs, and containerized SaMD deployment.

Session 3: Agentic AI Transforms Science from Molecules to Materials

Cornell’s Eun-Ah Kim and Harvard’s Marinka Zitnik will speak on March 18 at 3:00–3:40 p.m. PDT. They will explore agentic AI in drug development, quantum material simulation, and next-gen materials. AI agents generate verifiable hypotheses and embed physics principles. This synergy may unlock a new “Moore’s Law” for materials.

Session 4: Beyond Models—Accelerating Frontier Drug Discovery

David Ruau from NVIDIA will join leaders from Latent Labs, Owkin, and Apheris on March 18 at 4:00–4:50 a.m. PDT. They discuss surpassing model limits for breakthrough drugs. Focus areas include AI platforms, multimodal data integration, and large-scale protein simulations. Speakers share deployment experiences and future ecosystem collaboration among pharma, AI startups, and data providers to advance precision medicine.

Author

Steven Chung

紅杏枝頭春意鬧固然是眾人所追求的風景，但我願意說，青蘿拂行衣更能湧生感嘆。 願在海量晦澀的生醫資訊中，為您點亮一座心燈塔。鐘煌翔